The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 6, 1998, Pages 672-683

  Hale, Michael D ^b   Nicholls, Andrew J ^a   Bullingham, Roy E S ^b   Hené, Ronald ^b   Hoitsma, A ^b   Squifflet, Jean Paul ^b   Weimar, W ^b   Vanrenterghem, Yves ^b   Van De Woude, Fokko J ^b   Verpooten, Gert A ^b  

^a BIOGEN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AREA UNDER CURVE; DOUBLE-BLIND METHOD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 13044305870     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90058-3     Document Type: Article

References (16)

1. Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Trans Proc 1996;28:925-9.
2. Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit 1997;19:358-60.
3. Sanathanan LP, Peck CC. The randomized concentrationcontrolled trial: an evaluation of its sample size efficiency. Controlled Clin Trials 1991;12:780-94.
4. Peck CC. The randomized concentration-controlled clinical trial: an information-rich alternative to the randomized placebo-controlled clinical trial [abstract]. Clin Pharmacol Ther 1990;47:148.
5. Hale MD, Gillespie WR, Gupta SK, Tuk B, Holford NH. Clinical trial simulation: streamlining your drug development process. Appl Clin Trials 1996;5:35-40.
6. Hale MD. Using population pharmacokinetics for planning a randomized concentration-controlled trial with a binary response. In: Aarons L, Balant LP, Danhof M, Gex-Fabry M, Gundert-Remy UA, Karlsson MO, et al, editors. The population approach: measuring and managing variability in response, concentration, and dose. Belgium: European Commission; 1997. p. 227-35.
7. Tsina I, Chu F, Hama K, Kaloostian M, Tam YL, Tarnowski T, et al. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B Biomed Appl 1996;675:119-29.
8. Reeve RR, Hale M. Results and efficiency of Bayesian dose adjustment in a clinical trial with binary endpoint. ASA Proc Biopharm Sect 1994;324-7.
9. Solez K, Axelsen RA, Benediktsson H. Burdick JF, Cohen AH, Colvin RB, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993;44:411-22.
10. United States Food and Drug Administration. "COSTART" coding symbols for the thesaurus of adverse reaction terms. Rockville (MD): FDA; 1989.
11. [Anonymous]. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995;345:1321-5.
12. [Anonymous]. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61:1029-37.
13. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-32.
14. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley; 1989. p. 56.
15. JMP Statistics and Graphics Guide; version 3.1. Cary (NC): SAS Institute; 1995. p. 117.
16. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressivc effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;33:161-73.